The critical difference in ACMG secondary variant reporting lies in the detection of non-coding pathogenic variants. While both clinical exome sequencing (cES) and clinical genome sequencing (cGS) reliably report Class 4 (likely pathogenic) and Class 5 (pathogenic) variants within the coding regions of medically actionable genes, cGS adds the unique ability to identify rare, highly penetrant variants in the non-coding portions of those same ACMG genes. This means cGS can surface deep intronic or regulatory pathogenic variants that cES completely misses, directly influencing the completeness of secondary findings.
Secondary finding analysis under ACMG guidelines is fundamentally about catching hidden, life-threatening variants in a defined set of genes. cES captures the coding portion of that risk; cGS captures the entire genomic footprint of the gene, significantly expanding the scope of what can be reported from a single test.
Understanding ACMG Secondary Findings
The ACMG guidelines create a uniform reporting obligation for a specific set of actionable genes, even when they are unrelated to the primary diagnosis. Understanding how sequencing technology maps to this obligation is where cES and cGS truly diverge.
What the ACMG Guidelines Mandate
Secondary findings are actively sought out—they are not passive observations. ACMG recommendations require laboratories to deliberately analyze a curated panel of genes associated with inherited cancers, cardiovascular disorders, and metabolic diseases.
For each gene on that list, the lab must report any pathogenic or likely pathogenic variant found. The key constraint is that the search is explicitly not limited to the phenotype under investigation. The analysis must cover the entire gene regardless of why the patient was tested.
The Analytical Scope of cES vs. cGS
cES targets only the protein-coding exons, plus the immediate flanking intronic splice sites. This design deliberately excludes the vast bulk of introns, promoters, enhancers, and other non-coding regulatory elements.
cGS reads the entire gene structure from start to finish. It sequences not just the exons but every deep intronic region, untranslated region (UTR), and the upstream promoter. This coverage is critical because well-characterized pathogenic variants in ACMG genes—such as deep intronic splice-altering mutations in BRCA1 or LDLR—fall outside the capture footprint of cES and simply cannot be seen.
cES therefore enforces a systematic blind spot for non-coding pathogenic variation in secondary finding genes. cGS eliminates that blind spot by design.
Technical Capabilities That Directly Impact Reporting
The difference in secondary reporting is not just theoretical; it rests on concrete technical performance factors that influence whether a variant can be confidently called, classified, and reported.
Coverage Uniformity and Copy Number Variants
cES relies on capture probes that pull down target DNA. This process generates inherent sequence bias and uneven coverage across exons, often requiring high read depths (60×–100×) to compensate for signal gaps.
cGS uses PCR-free shotgun sequencing, resulting in highly uniform coverage across the entire genome at a lower average depth (~30×).
This uniformity directly upgrades secondary finding capabilities for copy number variants (CNVs). ACMG secondary findings genes frequently harbor pathogenic large deletions or duplications (e.g., in LDLR for familial hypercholesterolemia, or MLH1/MSH2 for Lynch syndrome). cGS can resolve CNVs down to ~500 base pairs, routinely detecting single-exon deletions. cES typically detects CNVs only at the scale of one to two exons and often fails to precisely map breakpoints, potentially leaving reportable structural variants ambiguous or invisible.
Data Burden and Bioinformatics Demands
cGS generates approximately 200 GB of data per sample, compared to 30–50 GB for cES. Storing, processing, and analyzing that volume demands a robust bioinformatics infrastructure.
For secondary reporting, the challenge compounds. A cGS pipeline must filter and interpret not just coding variants, but also the full set of non-coding changes in each ACMG gene. This dramatically increases the number of variants of uncertain significance (VUS) that must be classified and documented. Laboratories must invest in dedicated curation teams and standardized pipelines to keep this workload clinically manageable.
Understanding the Trade-offs
Implementing secondary reporting protocols is never a one-size-fits-all decision. Both approaches carry real operational and interpretive consequences.
The Interpretation Bottleneck
A more complete sequence does not automatically mean a clearer report. cGS will identify far more rare non-coding changes, the vast majority of which are benign or entirely uncharacterized. Each one of these, if located in an ACMG gene, must be evaluated.
This creates a substantial interpretation burden. Laboratories risk either over-reporting VUS (which can cause anxiety and unnecessary follow-up testing) or under-reporting by failing to recognize a truly pathogenic non-coding splice variant buried among noise. Specialist bioinformatics consulting and carefully curated variant databases become essential to navigate this grey zone.
Operational and Economic Considerations
cES carries a lower per-sample cost and faster turnaround time due to smaller data volumes and simpler analytics. For laboratories serving high-volume clinical operations, this simplicity can translate directly into consistent, guideline-compliant secondary reports with manageable interpretation overhead.
cGS requires a higher upfront investment in computing and storage, and its secondary analysis workflows are intrinsically more complex. However, it future-proofs the assay. As knowledge grows and more pathogenic non-coding variants are linked to the ACMG gene list, a cGS-derived data file can be re-analyzed without ever re-sequencing the patient.
Making the Right Choice for Your Laboratory
Your decision should hinge on the specific clinical mission you need to fulfill and the resources you have available today.
- If your primary focus is strictly complying with current ACMG recommendations for known coding variants: cES provides a cost-effective, well-established path. It will reliably capture the vast majority of actionable coding variants and should meet current regulatory standards, while acknowledging the systematic non-coding blind spot.
- If your primary focus is maximizing diagnostic yield and building a future-proof infrastructure: cGS is the superior long-term investment. It captures all variant types across all genomic regions in the ACMG gene list, enabling the most comprehensive secondary report possible and allowing retrospective re-analysis as new pathogenic regions are discovered.
- If your primary focus is minimizing interpretation burden and operational complexity: cES offers a simpler, more constrained landscape. The limited search space reduces the influx of VUS in secondary finding genes, making report generation faster and interpretation teams more efficient.
The test method you select for secondary findings ultimately shapes how much of a patient's genetic risk you can see. The right choice aligns your laboratory’s capacity for deep interpretation with your commitment to uncovering the full spectrum of actionable genomic information.
Summary Table:
| Comparison Metric | Clinical Exome Sequencing (cES) | Clinical Genome Sequencing (cGS) |
|---|---|---|
| Genomic Scope | Coding exons + immediate splice sites | Entire genomic sequence (exons, introns, UTRs, promoters) |
| Non-Coding Variant Detection | Blind to deep intronic & regulatory variants | Detects deep intronic & regulatory pathogenic variants |
| CNV Resolution | Resolves 1–2 exon scale deletions/duplications | Resolves down to ~500 bp (single-exon deletions) |
| Coverage Uniformity | Variable; prone to capture bias (60×–100× depth required) | High PCR-free uniformity (~30× depth) |
| Data & Interpretation Burden | Moderate (30–50 GB/sample; lower VUS volume) | High (~200 GB/sample; higher non-coding VUS volume) |
| Future Re-analysis Potential | Limited to re-annotating coding regions | High; re-analyzable as non-coding evidence evolves |
Elevate Your Clinical NGS & IVD Workflows with CamelBio
Whether you are scaling clinical exome sequencing assays or establishing high-throughput whole-genome diagnostic pipelines, overcoming assay development hurdles and maintaining consistent supply standards is vital.
CamelBio provides diagnostic manufacturers, clinical labs, and research institutes with one-stop access to premium IVD raw materials, technical services, and expert consulting—covering every stage of your product lifecycle from concept to clinic.
Looking to optimize your genomic assays or streamline compliance? Contact CamelBio today to discover how our tailored solutions can accelerate your diagnostic capabilities!